Work

A Phase 4, Open-label Study Evaluating the Safety and Tolerability of Once Daily Rimegepant for Episodic Migraine Prevention (P11-4.008)

Year: 2025

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000212738

Authors: Jeremias Antinew, Robert Fountaine, Vittorio Loprinzo, Esther Straghan, Terence Fullerton

Institutions: Pfizer (United States), Pfizer (United Kingdom)

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409222500

FWCI: 1.271

Cites:

Cited by: 2

Related to: 10